DK1784205T3 - Strækmærkebehandling med botulinumtoksin - Google Patents

Strækmærkebehandling med botulinumtoksin

Info

Publication number
DK1784205T3
DK1784205T3 DK05791811.2T DK05791811T DK1784205T3 DK 1784205 T3 DK1784205 T3 DK 1784205T3 DK 05791811 T DK05791811 T DK 05791811T DK 1784205 T3 DK1784205 T3 DK 1784205T3
Authority
DK
Denmark
Prior art keywords
botulinum toxin
stretch mark
mark treatment
stretch
treatment
Prior art date
Application number
DK05791811.2T
Other languages
English (en)
Inventor
Eric R First
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DK1784205T3 publication Critical patent/DK1784205T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK05791811.2T 2004-09-03 2005-08-24 Strækmærkebehandling med botulinumtoksin DK1784205T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/934,812 US7429386B2 (en) 2004-09-03 2004-09-03 Stretch mark treatment
PCT/US2005/030285 WO2006028724A1 (en) 2004-09-03 2005-08-24 Stretch mark treatment with botulinum toxic

Publications (1)

Publication Number Publication Date
DK1784205T3 true DK1784205T3 (da) 2010-06-21

Family

ID=35447629

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05791811.2T DK1784205T3 (da) 2004-09-03 2005-08-24 Strækmærkebehandling med botulinumtoksin

Country Status (10)

Country Link
US (1) US7429386B2 (da)
EP (1) EP1784205B1 (da)
KR (1) KR101211890B1 (da)
AT (1) ATE462443T1 (da)
AU (1) AU2005282967A1 (da)
CA (1) CA2581934C (da)
DE (1) DE602005020309D1 (da)
DK (1) DK1784205T3 (da)
ES (1) ES2340782T3 (da)
WO (1) WO2006028724A1 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120114697A1 (en) 2002-08-19 2012-05-10 Ira Sanders Treatment of holocrine gland dysfunction with clostridia neurotoxins
US7824693B2 (en) 2002-08-19 2010-11-02 Ira Sanders Treatment of fine wrinkles with clostridia neurotoxins
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US20060073208A1 (en) 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
US9044477B2 (en) * 2007-12-12 2015-06-02 Allergan, Inc. Botulinum toxin formulation
US9308070B2 (en) 2008-12-15 2016-04-12 Allergan, Inc. Pliable silk medical device
EP2421549B1 (en) * 2009-04-20 2013-06-12 Allergan, Inc. Silk fibroin hydrogels and uses thereof
FR2973246B1 (fr) 2011-03-31 2013-04-12 Nuxe Lab Composition a base de camellia japonica pour la protection de la peau.
FR2977797B1 (fr) 2011-07-13 2014-01-17 Urgo Lab Utilisation cosmetique et/ou dermatologique de composes oligosaccharidiques pour la prevention et le traitement des vergetures
WO2015126527A1 (en) * 2014-02-18 2015-08-27 Kaufman-Janette Joely Botulinum neurotoxin for use in the prophylactic treatment of cutaneous wounds
HUE055368T2 (hu) * 2016-08-12 2021-11-29 Biomup France Sas Vérzéscsillapító folyadék
EP3600221A4 (en) * 2017-03-22 2021-01-13 Bonti, Inc. BOTULINARY NEUROTOXINS FOR USE IN THERAPY
US11191819B2 (en) 2018-08-28 2021-12-07 Ira Sanders Skin therapeutics
KR102620242B1 (ko) 2019-10-31 2024-01-02 차의과학대학교 산학협력단 보툴리늄 독소 또는 이의 염을 포함하는 자궁 내막의 혈류량 증진용 조성물

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US613915A (en) * 1898-11-08 Manufacture of non-intoxicating beverages
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
EP0758900B1 (en) * 1994-05-09 2002-04-10 BINDER, William J. Botulinum toxin FOR REDUCTION OF migraine HEADACHE PAIN
US5670484A (en) * 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
KR100544060B1 (ko) * 1997-07-15 2006-01-23 더 리젠트스 오브 더 유니버시티 오브 콜로라도 비뇨기과학 및 관련 부전증을 치료하기 위한 신경독요법의 용도
US6063768A (en) * 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
US6660301B1 (en) 1998-03-06 2003-12-09 Biosphere Medical, Inc. Injectable microspheres for dermal augmentation and tissue bulking
EP0947433A1 (en) * 1998-04-03 1999-10-06 Tetra Laval Holdings & Finance SA Device for opening packages of pourable food products
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
WO2000024419A1 (en) * 1998-10-27 2000-05-04 Mayo Foundation For Medical Education And Research Methods for enhancing wound healing
DE19852981A1 (de) 1998-11-17 2000-05-18 Martin Schmidt Botulinum-Toxine, deren Derivate, Analoge und molekulare Bruchstücke zur topischen epicutanen Anwendung auch in Zusammenwirken mit hautpenetrationsfördernden Substanzen und Maßnahmen in Zubereitungsformen zur Beeinflussung acetylcholinabhängiger Körperfunktionen
GB9907429D0 (en) 1999-03-31 1999-05-26 Microbiological Res Authority Modulation of C-fibre activity
DE19925739A1 (de) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US6358917B1 (en) * 1999-08-24 2002-03-19 Jean D. A. Carruthers Cosmetic use of botulinum toxin for treatment of downturned mouth
GB9922554D0 (en) 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6265379B1 (en) * 1999-10-13 2001-07-24 Allergan Sales, Inc. Method for treating otic disorders
US6139845A (en) * 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US6143306A (en) * 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US6261572B1 (en) * 2000-01-11 2001-07-17 Allergan Sales, Inc. Method for treating a pancreatic disorder with a neurotoxin
US6753315B2 (en) * 2000-02-24 2004-06-22 Brown University Research Foundation α-bungarotoxin molecules and uses thereof
US6436424B1 (en) 2000-03-20 2002-08-20 Biosphere Medical, Inc. Injectable and swellable microspheres for dermal augmentation
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6299893B1 (en) * 2000-04-17 2001-10-09 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US6423319B1 (en) * 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
US6787517B1 (en) * 2000-12-29 2004-09-07 Allergan, Inc. Agent and methods for treating pain
DK1411978T3 (da) 2001-07-27 2009-01-05 Univ Louisiana State Botulinum-toksin ved behandlingen eller forebyggelsen af acne
US6623742B2 (en) * 2001-09-17 2003-09-23 Allergan, Inc. Methods for treating fibromyalgia
EP1487481A4 (en) * 2002-03-01 2005-11-23 Elan Pharm Inc METHOD FOR TREATING NERVE TERMINATION SYNDROMES
CN1383811A (zh) 2002-05-16 2002-12-11 卢伟成 一种除皱化妆品及其制作工艺
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions

Also Published As

Publication number Publication date
CA2581934C (en) 2012-11-27
CA2581934A1 (en) 2006-03-16
ES2340782T3 (es) 2010-06-09
AU2005282967A1 (en) 2006-03-16
US20060051377A1 (en) 2006-03-09
EP1784205A1 (en) 2007-05-16
WO2006028724A1 (en) 2006-03-16
US7429386B2 (en) 2008-09-30
EP1784205B1 (en) 2010-03-31
KR101211890B1 (ko) 2012-12-14
KR20070057908A (ko) 2007-06-07
DE602005020309D1 (de) 2010-05-12
ATE462443T1 (de) 2010-04-15

Similar Documents

Publication Publication Date Title
DK1784205T3 (da) Strækmærkebehandling med botulinumtoksin
DK2282766T3 (da) Suturlinie-indgivelsesteknik med anvendelse af botulinumtoksiner
AR065033A1 (es) Metodos para prevenir y tratar trastornos neurodegenerativos
NZ593111A (en) Antibacterial compounds
CY1114792T1 (el) Κλωστριδιακες τοξινες για χρηση στην θεραπεια προωρης εκσπερματισης
BR112012022125A2 (pt) composto, sal de dicloridrato, composição farmacêutica, uso do composto, e, método para tratar um paciente
DK1322324T3 (da) Fremgangsmåder til behandling af muskelskader
BRPI0411316A (pt) uso de uma toxina clostrìdica para reduzir o apetite
BR0309888A (pt) Tratamento intracraniano de distúrbios neuropsiquiátricos por neurotoxinas clostridiais tal como a toxina da botulina
BR0111698A (pt) Método para o tratamento de um distúrbio de movimento
ECSP11010980A (es) Compuestos heteroaromáticos espirocíclicos fusionados para el tratamiento de infecciones bacterianas
SG178952A1 (en) Chemical compounds
BR0312099A (pt) Uso de toxina bolutìnica, bem como composição farmacêutica
EA201000563A1 (ru) Триазолпиридиновые ингибиторы 11-бета- гидроксистероид - дегидрогеназы типа i
MX2012001654A (es) Metodos para usar moduladores de c-met.
TW200618808A (en) Methods for treating diverse cancers
MXPA05011470A (es) Metodos para tratar cefalea de senos.
NZ601350A (en) Method of treating arthritis
PT1492561E (pt) Metodo para tratar disturbios da glandula mamaria
NO20075119L (no) Nedbrytbare geler for anvendelse i soneisolering
DE602007002625D1 (de) Verwendung von botulintoxin zur linderung von hodenschmerzen
UA107562C2 (uk) Спосіб лікування псоріазу
BRPI0508254A (pt) métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos
MA32375B1 (fr) Derives de 5-hydroxymethyl-oxazolidine-2-one pour le traitement de maladies intestinales bacteriennes
MA33915B1 (fr) Nouveaux derives d' (heterocycle-piperidine condensee)-(piperazinyl)-1-alcanone ou d' (heterocycle-pyrrolidine condensee)-(piperazinyl)-1-alcanone et leur utilisation comme inhibiteurs de p75